Skip to main content

Advertisement

SpringerLink
Log in

Intratumoral Drug Delivery with Nanoparticulate Carriers

  • Expert Review
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

ABSTRACT

Stiff extracellular matrix, elevated interstitial fluid pressure, and the affinity for the tumor cells in the peripheral region of a solid tumor mass have long been recognized as significant barriers to diffusion of small-molecular-weight drugs and antibodies. However, their impacts on nanoparticle-based drug delivery have begun to receive due attention only recently. This article reviews biological features of many solid tumors that influence transport of drugs and nanoparticles and properties of nanoparticles relevant to their intratumoral transport, studied in various tumor models. We also discuss several experimental approaches employed to date for enhancement of intratumoral nanoparticle penetration. The impact of nanoparticle distribution on the effectiveness of chemotherapy remains to be investigated and should be considered in the design of new nanoparticulate drug carriers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

REFERENCES

  1. Jang SH, Wientjes MG, Lu D, Au JLS. Drug delivery and transport to solid tumors. Pharm Res. 2003;20(9):1337–50.

    PubMed  CAS  Google Scholar 

  2. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7(11):653–64.

    PubMed  CAS  Google Scholar 

  3. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387–92.

    PubMed  CAS  Google Scholar 

  4. Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, et al. Tensional homeostasis and the malignant phenotype. Cancer Cell. 2005;8(3):241–54.

    PubMed  CAS  Google Scholar 

  5. Young JS, Lumsden CE, Stalker AL. The significance of the “tissue pressure” of normal testicular and of neoplastic (Brown-Pearce carcinoma) tissue in the rabbit. J Pathol Bacteriol. 1950;62(3):313–33.

    PubMed  CAS  Google Scholar 

  6. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 2001;46(1–3):149–68.

    PubMed  CAS  Google Scholar 

  7. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvas Res. 1989;37(1):77–104.

    CAS  Google Scholar 

  8. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 1988;48(24 Pt 1):7022–32.

    PubMed  CAS  Google Scholar 

  9. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10(2):145–7.

    PubMed  CAS  Google Scholar 

  10. Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res. 1990;50(15):4478–84.

    PubMed  CAS  Google Scholar 

  11. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - An obstacle in cancer therapy. Nat Rev Cancer. 2004;4(10):806–13.

    PubMed  CAS  Google Scholar 

  12. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6(8):583–92.

    PubMed  CAS  Google Scholar 

  13. Kuh HJ, Jang SH, Wientjes MG, Weaver JR, Au JLS. Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther. 1999;290(2):871–80.

    PubMed  CAS  Google Scholar 

  14. Lankelma J, Dekker H, Luque RF, Luykx S, Hoekman K, van der Valk P, et al. Doxorubicin gradients in human breast cancer. Clin Cancer Res. 1999;5(7):1703–7.

    PubMed  CAS  Google Scholar 

  15. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7(9):771–82.

    PubMed  CAS  Google Scholar 

  16. Fleming JM, Miller TC, Quinones M, Xiao Z, Xu X, Meyer MJ, et al. The normal breast microenvironment of premenopausal women differentially influences the behavior of breast cancer cells in vitro and in vivo. BMC Med. 2010;8:27.

    PubMed  Google Scholar 

  17. Park K. A new ligand for targeted drug delivery to tumor stromal cells. J Control Release. 2010;145(2):75.

    PubMed  CAS  Google Scholar 

  18. Reed RK, Rubin K. Transcapillary exchange: role and importance of the interstitial fluid pressure and the extracellular matrix. Cardiovasc Res. 2010;87(2):211–7.

    PubMed  CAS  Google Scholar 

  19. Ushiki T. Collagen fibers, reticular fibers and elastic fibers. A comprehensive understanding from a morphological viewpoint. Arch Histol Cytol. 2002;65(2):109–26.

    PubMed  Google Scholar 

  20. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol. 2003;200(4):448–64.

    PubMed  CAS  Google Scholar 

  21. Barkan D, Green JE, Chambers AF. Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer. 2010;46(7):1181–8.

    PubMed  CAS  Google Scholar 

  22. Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem. 1998;67:609–52.

    PubMed  CAS  Google Scholar 

  23. Koninger J, Giese T, di Mola FF, Wente MN, Esposito I, Bachem MG, et al. Pancreatic tumor cells influence the composition of the extracellular matrix. Biochem Biophys Res Commun. 2004;322(3):943–9.

    PubMed  Google Scholar 

  24. Comalada M, Cardo M, Xaus J, Valledor AF, Lloberas J, Ventura F, et al. Decorin reverses the repressive effect of autocrine-produced TGF-beta on mouse macrophage activation. J Immunol. 2003;170(9):4450–6.

    PubMed  CAS  Google Scholar 

  25. Csordas G, Santra M, Reed CC, Eichstetter I, McQuillan DJ, Gross D, et al. Sustained down-regulation of the epidermal growth factor receptor by decorin - A mechanism for controlling tumor growth in vivo. J Biol Chem. 2000;275(42):32879–87.

    PubMed  CAS  Google Scholar 

  26. Schonherr E, Levkau B, Schaefer L, Kresse H, Walsh K. Decorin-mediated signal transduction in endothelial cells - Involvement of Akt/protein kinase B in up-regulation of p21(WAF1/CIP1) but not p27(KIP1). J Biol Chem. 2001;276(44):40687–92.

    PubMed  CAS  Google Scholar 

  27. Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature. 1990;346(6281):281–4.

    PubMed  CAS  Google Scholar 

  28. Theocharis AD, Vynios DH, Papageorgakopoulou N, Skandalisa SS, Theocharis DA. Altered content composition and structure of glycosaminoglycans and proteoglycans in gastric carcinoma. Int J Biochem Cell Biol. 2003;35(3):376–90.

    PubMed  CAS  Google Scholar 

  29. Reed CC, Gauldie J, Iozzo RV. Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. Oncogene. 2002;21(23):3688–95.

    PubMed  CAS  Google Scholar 

  30. Santra M, Skorski T, Calabretta B, Lattime EC, Iozzo RV. De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc Natl Acad Sci USA. 1995;92(15):7016–20.

    PubMed  CAS  Google Scholar 

  31. Teicher BA, Maehara Y, Kakeji Y, Ara G, Keyes SR, Wong J, et al. Reversal of in vivo drug resistance by the transforming growth factor-beta inhibitor decorin. Int J Cancer. 1997;71(1):49–58.

    PubMed  CAS  Google Scholar 

  32. Tsara ME, Theocharis AD, Theocharis DA. Compositional and structural alterations of proteoglycans in human rectum carcinoma with special reference to versican and decorin. Anticancer Res. 2002;22(5):2893–8.

    PubMed  CAS  Google Scholar 

  33. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009;139(5):891–906.

    PubMed  CAS  Google Scholar 

  34. Butcher DT, Alliston T, Weaver VM. A tense situation: forcing tumour progression. Nat Rev Cancer. 2009;9(2):108–22.

    PubMed  CAS  Google Scholar 

  35. Kresse H, Schonherr E. Proteoglycans of the extracellular matrix and growth control. J Cell Physiol. 2001;189(3):266–74.

    PubMed  CAS  Google Scholar 

  36. Park CC, Rembert J, Chew K, Moore D, Kerlikowske K. High mammographic breast density is independent predictor of local but not distant recurrence after lumpectomy and radiotherapy for invasive breast cancer. Int J Radiat Oncol Biol Phys. 2009;73(1):75–9.

    PubMed  Google Scholar 

  37. Kolacna L, Bakesova J, Varga F, Kostakova E, Planka L, Necas A, et al. Biochemical and biophysical aspects of collagen nanostructure in the extracellular matrix. Physiol Res. 2007;56 Suppl 1:S51–60.

    PubMed  CAS  Google Scholar 

  38. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet. 2003;33(1):49–54.

    PubMed  CAS  Google Scholar 

  39. Feng YM, Sun BC, Li XQ, Zhang L, Niu Y, Xiao CH, et al. Differentially expressed genes between primary cancer and paired lymph node metastases predict clinical outcome of node-positive breast cancer patients. Breast Cancer Res Treat. 2007;103(3):319–29.

    PubMed  CAS  Google Scholar 

  40. Calvo A, Catena R, Noble MS, Carbott D, Gil-Bazo I, Gonzalez-Moreno O, et al. Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene. 2008;27(40):5373–84.

    PubMed  CAS  Google Scholar 

  41. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 2000;60(9):2497–503.

    PubMed  CAS  Google Scholar 

  42. Pfeiffer BJ, Franklin CL, Hsieh FH, Bank RA, Phillips CL. Alpha 2(I) collagen deficient oim mice have altered biomechanical integrity, collagen content, and collagen crosslinking of their thoracic aorta. Matrix Biol. 2005;24(7):451–8.

    PubMed  CAS  Google Scholar 

  43. Erler JT, Weaver VM. Three-dimensional context regulation of metastasis. Clin Exp Metastasis. 2009;26(1):35–49.

    PubMed  Google Scholar 

  44. Postovit LM, Abbott DE, Payne SL, Wheaton WW, Margaryan NV, Sullivan R, et al. Hypoxia/reoxygenation: a dynamic regulator of lysyl oxidase-facilitated breast cancer migration. J Cell Biochem. 2008;103(5):1369–78.

    PubMed  CAS  Google Scholar 

  45. Albinger-Hegyi A, Stoeckli SJ, Schmid S, Storz M, Iotzova G, Probst-Hensch NM, et al. Lysyl oxidase expression is an independent marker of prognosis and a predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC). Int J Cancer. 2010;126(11):2653–62.

    PubMed  CAS  Google Scholar 

  46. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9–22.

    PubMed  CAS  Google Scholar 

  47. Stupack DG, Puente XS, Boutsaboualoy S, Storgard CM, Cheresh DA. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol. 2001;155(3):459–70.

    PubMed  CAS  Google Scholar 

  48. Zhao HB, Ross FP, Teitelbaum SL. Unoccupied alpha(v)beta(3) integrin regulates osteoclast apoptosis by transmitting a positive death signal. Mol Endocrinol. 2005;19(3):771–80.

    PubMed  CAS  Google Scholar 

  49. Sawada Y, Tamada M, Dubin-Thaler BJ, Cherniavskaya O, Sakai R, Tanaka S, et al. Force sensing by mechanical extension of the Src family kinase substrate p130Cas. Cell. 2006;127(5):1015–26.

    PubMed  CAS  Google Scholar 

  50. Miranti CK, Brugge JS. Sensing the environment: a historical perspective on integrin signal transduction. Nat Cell Biol. 2002;4(4):E83–90.

    PubMed  CAS  Google Scholar 

  51. Han SW, Khuri FR, Roman J. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res. 2006;66(1):315–23.

    PubMed  CAS  Google Scholar 

  52. Vellon L, Menendez JA, Lupu R. alpha(v)beta(3) integrin regulates Heregulin (HRG)-induced cell proliferation and survival in breast cancer. Oncogene. 2005;24(23):3759–73.

    PubMed  CAS  Google Scholar 

  53. Bohme U, Scheler U. Effective charge of bovine serum albumin determined by electrophoresis NMR. Chem Phys Lett. 2007;435:342–5.

    Google Scholar 

  54. Lohle PNM, Verhagen I, Teelken AW, Blaauw EH, Go KG. The pathogenesis of cerebral gliomatous cysts. Neurosurgery. 1992;30(2):180–5.

    PubMed  CAS  Google Scholar 

  55. Ding Y, Bian X, Yao W, Li R, Ding D, Hu Y, et al. Surface-potential-regulated transmembrane and cytotoxicity of chitosan/gold hybrid nanospheres. ACS Appl Mater Interfaces. 2010;2(5):1456–65.

    PubMed  CAS  Google Scholar 

  56. Asadishad B, Vosoughi M, Alamzadeh I, Tavakoli A. Synthesis of folate-modified, polyethylene glycol-functionalized gold nanoparticles for targeted drug delivery. J Dispers Sci Technol. 2010;31(4):492–500.

    CAS  Google Scholar 

  57. Cho WS, Cho M, Jeong J, Choi M, Han BS, Shin HS, et al. Size-dependent tissue kinetics of PEG-coated gold nanoparticles. Toxicol Appl Pharmacol. 2010;245(1):116–23.

    PubMed  CAS  Google Scholar 

  58. Pornpattananangkul D, Olson S, Aryal S, Sartor M, Huang CM, Vecchio K, et al. Stimuli-responsive liposome fusion mediated by gold nanoparticles. ACS Nano. 2010;4(4):1935–42.

    PubMed  CAS  Google Scholar 

  59. Wang HJ, Zhao PQ, Liang XF, Gong XQ, Song T, Niu RF, et al. Folate-PEG coated cationic modified chitosan - Cholesterol liposomes for tumor-targeted drug delivery. Biomaterials. 2010;31(14):4129–38.

    PubMed  CAS  Google Scholar 

  60. Mevel M, Kamaly N, Carmona S, Oliver MH, Jorgensen MR, Crowther C, et al. DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA. J Control Release. 2010;143(2):222–32.

    PubMed  CAS  Google Scholar 

  61. Barua S, Rege K. The influence of mediators of intracellular trafficking on transgene expression efficacy of polymer-plasmid DNA complexes. Biomaterials. 2010;31(22):5894–902.

    PubMed  CAS  Google Scholar 

  62. Contreras J, Xie J, Chen YJ, Pei H, Zhang G, Fraser CL, et al. Intracellular uptake and trafficking of difluoroboron dibenzoylmethane-polylactide nanoparticles in HeLa cells. ACS Nano. 2010;4(5):2735–47.

    PubMed  CAS  Google Scholar 

  63. Ravindran J, Nair HB, Sung BY, Prasad S, Tekmal RR, Aggarwal BB. Thymoquinone poly (lactide-co-glycolide) nanoparticles exhibit enhanced anti-proliferative, anti-inflammatory, and chemosensitization potential. Biochem Pharmacol. 2010;79(11):1640–7.

    PubMed  CAS  Google Scholar 

  64. Michel CC, Curry FE. Microvascular permeability. Physiol Rev. 1999;79(3):703–61.

    PubMed  CAS  Google Scholar 

  65. Aukland K, Reed RK. Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. Physiol Rev. 1993;73(1):1–78.

    PubMed  CAS  Google Scholar 

  66. Clark RA, Folkvord JM, Hart CE, Murray MJ, McPherson JM. Platelet isoforms of platelet-derived growth factor stimulate fibroblasts to contract collagen matrices. J Clin Invest. 1989;84(3):1036–40.

    PubMed  CAS  Google Scholar 

  67. Gullberg D, Tingstrom A, Thuresson AC, Olsson L, Terracio L, Borg TK, et al. Beta 1 integrin-mediated collagen gel contraction is stimulated by PDGF. Exp Cell Res. 1990;186(2):264–72.

    PubMed  CAS  Google Scholar 

  68. Montesano R, Orci L. Transforming growth factor beta stimulates collagen-matrix contraction by fibroblasts: implications for wound healing. Proc Natl Acad Sci USA. 1988;85(13):4894–7.

    PubMed  CAS  Google Scholar 

  69. Milosevic A, Fyles A, Hedley D, Hill R. The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol. 2004;14(3):249–58.

    PubMed  Google Scholar 

  70. Lunt SJ, Chaudary N, Hill RP. The tumor microenvironment and metastatic disease. Clin Exp Metastasis. 2009;26(1):19–34.

    PubMed  Google Scholar 

  71. Rofstad EK, Ruud EBM, Mathiesen B, Galappathi K. Associations between radiocurability and interstitial fluid pressure in human tumor xenografts without hypoxic tissue. Clin Cancer Res. 2010;16(3):936–45.

    PubMed  CAS  Google Scholar 

  72. Curti BD, Urba WJ, Alvord WG, Janik JE, Smith JW, Madara K, et al. Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment. Cancer Res. 1993;53(10 Suppl):2204–7.

    PubMed  CAS  Google Scholar 

  73. Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 2000;60(19):5565–70.

    PubMed  CAS  Google Scholar 

  74. Aukland K. Interstitial fluid balance in experimental animals and man. In: Staub NC, Hogg JC, Hargens AR, editors. Advances in Microcirculation, Vol 13 Interstitial-Lymphatic Liquid and Solute Movement; Satellite Symposium, Victoria, British Columbia, Canada, July 20–24, 1986 X + 290p S Karger Ag: Basel, Switzerland; New York, New York, USA Illus:110–123; 1987.

  75. Hofmann M, McCormack E, Mujic M, Rossberg M, Bernd A, Bereiter-Hahn J, et al. Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumor model. Neoplasia. 2009;11(8):812–22.

    PubMed  CAS  Google Scholar 

  76. Boucher Y, Kirkwood JM, Opacic D, Desantis M, Jain RK. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res. 1991;51(24):6691–4.

    PubMed  CAS  Google Scholar 

  77. Gutmann R, Leunig M, Feyh J, Goetz AE, Messmer K, Kastenbauer E, et al. Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. Cancer Res. 1992;52(7):1993–5.

    PubMed  CAS  Google Scholar 

  78. Nathanson SD, Nelson L. Interstitial fluid pressure in breast cancer, benign breast conditions, and breast parenchyma. Ann Surg Oncol. 1994;1(4):333–8.

    PubMed  CAS  Google Scholar 

  79. Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 2002;62(19):5476–84.

    PubMed  CAS  Google Scholar 

  80. Milosevic M, Fyles A, Hedley D, Pintilie M, Levin W, Manchul L, et al. Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor - oxygen measurements. Cancer Res. 2001;61(17):6400–5.

    PubMed  CAS  Google Scholar 

  81. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249–57.

    PubMed  CAS  Google Scholar 

  82. Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res. 2000;60(16):4324–7.

    PubMed  CAS  Google Scholar 

  83. Klosowska-Wardega A, Hasumi Y, Burmakin M, Ahgren A, Stuhr L, Moen I, et al. Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma. PLoS One. 2009;4(12):e8149.

    PubMed  Google Scholar 

  84. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol. 2007;8(6):464–78.

    PubMed  CAS  Google Scholar 

  85. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146(5):1029–39.

    PubMed  CAS  Google Scholar 

  86. Pietras K, Stumm M, Hubert M, Buchdunger E, Rubin K, Heldin CH, et al. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res. 2003;9(10 Pt 1):3779–87.

    PubMed  CAS  Google Scholar 

  87. Ostman A, Heldin CH. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv Cancer Res. 2001;80:1–38.

    PubMed  CAS  Google Scholar 

  88. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol. 2003;200(4):500–3.

    PubMed  CAS  Google Scholar 

  89. Rofstad EK, Gaustad JV, Brurberg KG, Mathiesen B, Galappathi K, Simonsen TG. Radiocurability is associated with interstitial fluid pressure in human tumor xenografts. Neoplasia. 2009;11(11):1243–51.

    PubMed  CAS  Google Scholar 

  90. Rofstad EK, Tunheim SH, Mathiesen B, Graff BA, Halsør EF, Nilsen K, et al. Pulmonary and lymph node metastasis is associated with primary tumor interstitial fluid pressure in human melanoma xenografts. Cancer Res. 2002;62(3):661–4.

    PubMed  CAS  Google Scholar 

  91. Hofmann M, Guschel M, Bernd A, Bereiter-Hahn J, Kaufmann R, Tandi C, et al. Lowering of tumor interstitial fluid pressure reduces tumor cell proliferation in a xenograft tumor model. Neoplasia. 2006;8(2):89–95.

    PubMed  Google Scholar 

  92. Hofmann M, Schultz M, Bernd A, Bereiter-Hahn J, Kaufmann R, Kippenberger S. Long-term lowering of tumour interstitial fluid pressure reduces Ki-67 expression. J Biomech. 2007;40(10):2324–9.

    PubMed  Google Scholar 

  93. Boucher Y, Jain RK. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res. 1992;52(18):5110–4.

    PubMed  CAS  Google Scholar 

  94. Jain RK. Barriers to drug delivery in solid tumors. Sci Am. 1994;271(1):58–65.

    PubMed  CAS  Google Scholar 

  95. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987;47(12):3039–51.

    PubMed  CAS  Google Scholar 

  96. Cho YW, Park SA, Han TH, Son DH, Park JS, Oh SJ, et al. In vivo tumor targeting and radionuclide imaging with self-assembled nanoparticles: mechanisms, key factors, and their implications. Biomaterials. 2007;28(6):1236–47.

    PubMed  CAS  Google Scholar 

  97. Choi KY, Min KH, Na JH, Choi K, Kim K, Park JH, et al. Self-assembled hyaluronic acid nanoparticles as a potential drug carrier for cancer therapy: synthesis, characterization, and in vivo biodistribution. J Mater Chem. 2009;19(24):4102–7.

    CAS  Google Scholar 

  98. Park K, Kim J-H, Nam YS, Lee S, Nam HY, Kim K, et al. Effect of polymer molecular weight on the tumor targeting characteristics of self-assembled glycol chitosan nanoparticles. J Control Release. 2007;122(3):305–14.

    PubMed  CAS  Google Scholar 

  99. ElBayoumi TA, Torchilin VP. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res. 2009;5(6):1973–80.

    Google Scholar 

  100. Gullotti E, Yeo Y. Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol Pharm. 2009;6(4):1041–51.

    PubMed  CAS  Google Scholar 

  101. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong KL, Nielsen UB, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006;66(13):6732–40.

    PubMed  CAS  Google Scholar 

  102. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA. 2007;104(39):15549–54.

    PubMed  CAS  Google Scholar 

  103. Zhang X, Koh CG, Yu B, Liu S, Piao L, Marcucci G, et al. Transferrin receptor targeted lipopolyplexes for delivery of antisense oligonucleotide g3139 in a murine k562 xenograft model. Pharm Res. 2009;26(6):1516–24.

    PubMed  CAS  Google Scholar 

  104. Nomura T, Koreeda N, Yamashita F, Takakura Y, Hashida M. Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissue-isolated tumors. Pharm Res. 1998;15(1):128–32.

    PubMed  CAS  Google Scholar 

  105. Reddy LH, Sharma RK, Murthy RSR. Enhanced tumour uptake of doxorubicin loaded Poly(butyl cyanoacrylate) nanoparticles in mice bearing Dalton’s lymphoma tlimour. J Drug Target. 2004;12(7):443–51.

    PubMed  CAS  Google Scholar 

  106. Bae Y, Nishiyama N, Fukushima S, Koyama H, Yasuhiro M, Kataoka K. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug Chem. 2005;16(1):122–30.

    PubMed  CAS  Google Scholar 

  107. Goodman TT, Chen JY, Matveev K, Pun SH. Spatio-temporal modeling of nanoparticle delivery to multicellular tumor spheroids. Biotechnol Bioeng. 2008;101(2):388–99.

    PubMed  CAS  Google Scholar 

  108. Lee H, Fonge H, Hoang B, Reilly RM, Allen C. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Mol Pharm. 2010;7(4):1195–208.

    PubMed  CAS  Google Scholar 

  109. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm. 2008;5(4):487–95.

    PubMed  CAS  Google Scholar 

  110. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307(1):93–102.

    PubMed  CAS  Google Scholar 

  111. Wang J, Sui M, Fan W. Nanoparticles for tumor targeted therapies and their pharmacokinetics. Curr Drug Metab. 2010;11(2):129–41.

    PubMed  CAS  Google Scholar 

  112. Campbell RB, Fukumura D, Brown EB, Mazzola LM, Izumi Y, Jain RK, et al. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res. 2002;62(23):6831–6.

    PubMed  CAS  Google Scholar 

  113. Dellian M, Yuan F, Trubetskoy VS, Torchilin VP, Jain RK. Vascular permeability in a human tumour xenograft: molecular charge dependence. Br J Cancer. 2000;82(9):1513–8.

    PubMed  CAS  Google Scholar 

  114. Kim B, Han G, Toley BJ, Kim CK, Rotello VM, Forbes NS. Tuning payload delivery in tumour cylindroids using gold nanoparticles. Nat Nanotechnol. 2010;5(6):465–72.

    PubMed  CAS  Google Scholar 

  115. Stylianopoulos T, Poh MZ, Insin N, Bawendi MG, Fukumura D, Munn LL, et al. Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions. Biophys J. 2010;99(5):1342–9.

    PubMed  CAS  Google Scholar 

  116. Lieleg O, Baumgärtel RM, Bausch AR. Selective filtering of particles by the extracellular matrix: an electrostatic bandpass. Biophys J. 2009;97(6):1569–77.

    PubMed  CAS  Google Scholar 

  117. Mamot C, Drummond DC, Noble CO, Kallab V, Guo ZX, Hong KL, et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005;65(24):11631–8.

    PubMed  CAS  Google Scholar 

  118. Gabizon A, Horowitz AT, Goren D, Tzemach D, Shmeeda H, Zalipsky S. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin Cancer Res. 2003;9(17):6551–9.

    PubMed  CAS  Google Scholar 

  119. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA. 2006;103(16):6315–20.

    PubMed  CAS  Google Scholar 

  120. Juweid M, Neumann R, Paik C, Perez-Bacete MJ, Sato J, van Osdol W, et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 1992;52(19):5144–53.

    PubMed  CAS  Google Scholar 

  121. Graff CP, Wittrup KD. Theoretical analysis of antibody targeting of tumor spheroids. Cancer Res. 2003;63(6):1288–96.

    PubMed  CAS  Google Scholar 

  122. Lo CM, Wang HB, Dembo M, Wang YL. Cell movement is guided by the rigidity of the substrate. Biophys J. 2000;79(1):144–52.

    PubMed  CAS  Google Scholar 

  123. Jiang J, Moore JS, Edelhauser HF, Prausnitz MR. Intrascleral drug delivery to the eye using hollow microneedles. Pharm Res. 2009;26(2):395–403.

    PubMed  CAS  Google Scholar 

  124. Zhang Y, So MK, Rao JH. Protease-modulated cellular uptake of quantum dots. Nano Lett. 2006;6(9):1988–92.

    PubMed  CAS  Google Scholar 

  125. Eikenes L, Tari M, Tufto I, Bruland OS, Davies CD. Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx (TM)) in human osteosarcoma xenografts. Br J Cancer. 2005;93(1):81–8.

    PubMed  CAS  Google Scholar 

  126. Kerbel RS, St Croix B, Florenes VA, Rak J. Induction and reversal of cell adhesion-dependent multicellular drug resistance in solid breast tumors. Hum Cell. 1996;9(4):257–64.

    PubMed  CAS  Google Scholar 

  127. St Croix B, Man S, Kerbel RS. Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors. Cancer Lett. 1998;131(1):35–44.

    PubMed  CAS  Google Scholar 

  128. Baumgartner G, Gomar-Höss C, Sakr L, Ulsperger E, Wogritsch C. The impact of extracellular matrix on the chemoresistance of solid tumors - experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett. 1998;131(1):85–99.

    PubMed  CAS  Google Scholar 

  129. Brown E, McKee T, diTomaso E, Pluen A, Seed B, Boucher Y, et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med. 2003;9(6):796–800.

    PubMed  CAS  Google Scholar 

  130. Novak K. Measuring the matrix. Nat Rev Cancer. 2003;3:394.

    CAS  Google Scholar 

  131. Kuhn SJ, Finch SK, Hallahan DE, Giorgio TD. Proteolytic surface functionalization enhances in vitro magnetic nanoparticle mobility through extracellular matrix. Nano Lett. 2006;6(2):306–12.

    PubMed  CAS  Google Scholar 

  132. Goodman TT, Olive PL, Pun SH. Increased nanoparticle penetration in collagenase-treated multicellular spheroids. Int J Nanomedicine. 2007;2(2):265–74.

    PubMed  CAS  Google Scholar 

  133. Jain RK. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat Rev Cancer. 2008;8(4):309–16.

    PubMed  CAS  Google Scholar 

  134. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58–62.

    PubMed  CAS  Google Scholar 

  135. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004;64(11):3731–6.

    PubMed  CAS  Google Scholar 

  136. Altmann KH, Wartmann M, O’Reilly T. Epothilones and related structures - a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta. 2000;1470(3):M79–91.

    PubMed  CAS  Google Scholar 

  137. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995;55(11):2325–33.

    PubMed  CAS  Google Scholar 

  138. Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed RK, Heldin CH, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 2001;61(7):2929–34.

    PubMed  CAS  Google Scholar 

  139. Lee I, Boucher Y, Jain RK. Nicotinamide can lower tumor interstitial fluid pressure: mechanistic and therapeutic implications. Cancer Res. 1992;52(11):3237–40.

    PubMed  CAS  Google Scholar 

  140. Kristjansen PEG, Boucher Y, Jain RK. Dexamethasone reduces the interstitial fluid pressure in a human colon adenocarcinoma xenograft. Cancer Res. 1993;53(20):4764–6.

    PubMed  CAS  Google Scholar 

  141. Kristensen CA, Nozue M, Boucher Y, Jain RK. Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. Br J Cancer. 1996;74(4):533–6.

    PubMed  CAS  Google Scholar 

  142. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest. 2002;110(4):475–82.

    PubMed  CAS  Google Scholar 

  143. Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A. Enhancement of tumor necrosis factor a antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol. 2000;18(11):1185–90.

    PubMed  CAS  Google Scholar 

  144. Rubin K, Sjoquist M, Gustafsson AM, Isaksson B, Salvessen G, Reed RK. Lowering of tumoral interstitial fluid pressure by prostaglandin E-1 is paralleled by an increased uptake of Cr-51-EDTA. Int J Cancer. 2000;86(5):636–43.

    PubMed  CAS  Google Scholar 

  145. Salnikov AV, Iversen VV, Koisti M, Sundberg C, Johansson L, Stuhr LB, et al. Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy. FASEB J. 2003;17(12):1756–8.

    PubMed  CAS  Google Scholar 

  146. Emerich DF, Dean RL, Snodgrass P, Lafreniere D, Agostino M, Wiens T, et al. Bradykinin modulation of tumor vasculature: II. Activation of nitric oxide and phospholipase A(2)/prostaglandin signaling pathways synergistically modifies vascular physiology and morphology to enhance delivery of chemotherapeutic agents to tumors. J Pharmacol Exp Ther. 2001;296(2):632–41.

    PubMed  CAS  Google Scholar 

  147. Lammerts E, Roswall P, Sundberg C, Gotwals PJ, Koteliansky VE, Reed RK, et al. Interference with TGF-beta 1 and -beta 3 in tumor stroma lowers tumor interstitial fluid pressure independently of growth in experimental carcinoma. Int J Cancer. 2002;102(5):453–62.

    PubMed  CAS  Google Scholar 

  148. Brekken C, Davies CD. Hyaluronidase reduces the interstitial fluid pressure in solid tumours in a non-linear concentration-dependent manner. Cancer Lett. 1998;131(1):65–70.

    PubMed  CAS  Google Scholar 

  149. Jang SH, Wientjes MG, Au JLS. Determinants of paclitaxel uptake, accumulation and retention in solid tumors. Invest New Drugs. 2001;19(2):113–23.

    PubMed  CAS  Google Scholar 

  150. Zheng JH, Chen CT, Au JLS, Wientjes MG. Time- and concentration-dependent penetration of doxorubicin in prostate tumors. AAPS PharmSci. 2001;3(2):E15.

    PubMed  CAS  Google Scholar 

  151. Jang SH, Wientjes MG, Au JLS. Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. J Pharmacol Exp Ther. 2001;296(3):1035–42.

    PubMed  CAS  Google Scholar 

  152. Lu Z, Tsai M, Lu D, Wang J, Wientjes MG, Au JLS. Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer. J Pharmacol Exp Ther. 2008;327(3):673–82.

    PubMed  CAS  Google Scholar 

  153. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res. 1999;59(15):3776–82.

    PubMed  CAS  Google Scholar 

  154. Kuhn SJ, Hallahan DE, Giorgio TD. Characterization of superparamagnetic nanoparticle interactions with extracellular matrix in an in vitro system. Ann Biomed Eng. 2006;34(1):51–8.

    PubMed  Google Scholar 

  155. Ahmed M, Goldberg SN. Combination radiofrequency thermal ablation and adjuvant IV liposomal doxorubicin increases tissue coagulation and intratumoural drug accumulation. Int J Hyperthermia. 2004;20(7):781–802.

    PubMed  CAS  Google Scholar 

  156. Goldberg SN, Saldinger PF, Gazelle GS, Huertas JC, Stuart KE, Jacobs T, et al. Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intratumoral doxorubicin injection in a rat breast tumor model. Radiology. 2001;220(2):420–7.

    PubMed  CAS  Google Scholar 

  157. Goldberg SN, Girnan GD, Lukyanov AN, Ahmed M, Monsky WL, Gazelle GS, et al. Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model. Radiology. 2002;222(3):797–804.

    PubMed  Google Scholar 

  158. Monsky WL, Kruskal JB, Lukyanov AN, Girnun GD, Ahmed M, Gazelle GS, et al. Radio-frequency ablation increases intratumoral liposomal doxorubicin accumulation in a rat breast tumor model. Radiology. 2002;224(3):823–9.

    PubMed  CAS  Google Scholar 

  159. Zhang A, Mi X, Yang G, Xu LX. Numerical study of thermally targeted liposomal drug delivery in tumor. J Heat Transfer. 2009;131:043209.

    Google Scholar 

  160. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51(4):691–744.

    PubMed  CAS  Google Scholar 

  161. Lee H, Hoang B, Fonge H, Reilly R, Allen C. In vitro distribution of polymeric nanoparticles at the whole-body, tumor, and cellular levels. Pharm Res. 2010;27(11):2343–55.

    PubMed  CAS  Google Scholar 

  162. Geng Y, Dalhaimer P, Cai S, Tsai R, Tewari M, Minko T, et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol. 2007;2(4):249–55.

    PubMed  CAS  Google Scholar 

  163. Fox ME, Szoka FC, Fréchet JMJ. Soluble polymer carriers for the treatment of cancer: the importance of molecular architecture. Acc Chem Res. 2009;42(8):1141–51.

    PubMed  CAS  Google Scholar 

Download references

ACKNOWLEDGMENTS

This study was supported by a grant from the Lilly Endowment, Inc., to the School of Pharmacy and Pharmaceutical Sciences, Purdue University, and the NIH R21 CA135130.

Author information

Authors and Affiliations

  1. Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, Indiana, 47907, USA

    Hillary Holback & Yoon Yeo

  2. Department of Industrial and Physical Pharmacy, College of Pharmacy, and Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana, 47907, USA

    Yoon Yeo

Authors
  1. Hillary Holback
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoon Yeo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoon Yeo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Holback, H., Yeo, Y. Intratumoral Drug Delivery with Nanoparticulate Carriers. Pharm Res 28, 1819–1830 (2011). https://doi.org/10.1007/s11095-010-0360-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-010-0360-y

KEY WORDS

Search

Navigation